|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 38858 |
FusionGeneSummary for TNFRSF14_C1QA |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: TNFRSF14_C1QA | Fusion gene ID: 38858 | Hgene | Tgene | Gene symbol | TNFRSF14 | C1QA | Gene ID | 8764 | 712 |
| Gene name | TNF receptor superfamily member 14 | complement C1q A chain | |
| Synonyms | ATAR|CD270|HVEA|HVEM|LIGHTR|TR2 | - | |
| Cytomap | 1p36.32 | 1p36.12 | |
| Type of gene | protein-coding | protein-coding | |
| Description | tumor necrosis factor receptor superfamily member 14CD40-like proteinherpes virus entry mediator Atumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)tumor necrosis factor receptor-like gene2 | complement C1q subcomponent subunit Acomplement C1q chain Acomplement component 1, q subcomponent, A chaincomplement component 1, q subcomponent, alpha polypeptidecomplement component C1q, A chain | |
| Modification date | 20180522 | 20180523 | |
| UniProtAcc | Q92956 | P02745 | |
| Ensembl transtripts involved in fusion gene | ENST00000409119, ENST00000355716, ENST00000442392, | ENST00000374642, ENST00000402322, | |
| Fusion gene scores | * DoF score | 3 X 3 X 2=18 | 2 X 3 X 1=6 |
| # samples | 3 | 3 | |
| ** MAII score | log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(3/6*10)=2.32192809488736 | |
| Context | PubMed: TNFRSF14 [Title/Abstract] AND C1QA [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | AI739187 | TNFRSF14 | chr1 | 2495102 | - | C1QA | chr1 | 22965505 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000409119 | ENST00000374642 | TNFRSF14 | chr1 | 2495102 | - | C1QA | chr1 | 22965505 | - |
| intron-3CDS | ENST00000409119 | ENST00000402322 | TNFRSF14 | chr1 | 2495102 | - | C1QA | chr1 | 22965505 | - |
| 3UTR-3CDS | ENST00000355716 | ENST00000374642 | TNFRSF14 | chr1 | 2495102 | - | C1QA | chr1 | 22965505 | - |
| 3UTR-3CDS | ENST00000355716 | ENST00000402322 | TNFRSF14 | chr1 | 2495102 | - | C1QA | chr1 | 22965505 | - |
| intron-3CDS | ENST00000442392 | ENST00000374642 | TNFRSF14 | chr1 | 2495102 | - | C1QA | chr1 | 22965505 | - |
| intron-3CDS | ENST00000442392 | ENST00000402322 | TNFRSF14 | chr1 | 2495102 | - | C1QA | chr1 | 22965505 | - |
Top |
FusionProtFeatures for TNFRSF14_C1QA |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| TNFRSF14 | C1QA |
| Receptor for BTLA. Receptor for TNFSF14/LIGHT andhomotrimeric TNFSF1/lymphotoxin-alpha. Involved in lymphocyteactivation. Plays an important role in HSV pathogenesis because itenhanced the entry of several wild-type HSV strains of bothserotypes into CHO cells, and mediated HSV entry into activatedhuman T-cells. {ECO:0000269|PubMed:8898196}. (Microbial infection) Acts as a receptor for Herpessimplex virus 1/HHV-1. {ECO:0000269|PubMed:11511370,ECO:0000269|PubMed:9696799}. (Microbial infection) Acts as a receptor for Herpessimplex virus 2/HHV-2. {ECO:0000269|PubMed:11511370,ECO:0000269|PubMed:9696799}. | C1q associates with the proenzymes C1r and C1s to yieldC1, the first component of the serum complement system. Thecollagen-like regions of C1q interact with the Ca(2+)-dependentC1r(2)C1s(2) proenzyme complex, and efficient activation of C1takes place on interaction of the globular heads of C1q with theFc regions of IgG or IgM antibody present in immune complexes. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for TNFRSF14_C1QA |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for TNFRSF14_C1QA |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for TNFRSF14_C1QA |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | C1QA | P02745 | DB00002 | Cetuximab | Complement C1q subcomponent subunit A | biotech | approved |
| Tgene | C1QA | P02745 | DB00051 | Adalimumab | Complement C1q subcomponent subunit A | biotech | approved |
| Tgene | C1QA | P02745 | DB00054 | Abciximab | Complement C1q subcomponent subunit A | biotech | approved |
| Tgene | C1QA | P02745 | DB00073 | Rituximab | Complement C1q subcomponent subunit A | biotech | approved |
| Tgene | C1QA | P02745 | DB00005 | Etanercept | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Tgene | C1QA | P02745 | DB00056 | Gemtuzumab ozogamicin | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Tgene | C1QA | P02745 | DB00072 | Trastuzumab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Tgene | C1QA | P02745 | DB00074 | Basiliximab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Tgene | C1QA | P02745 | DB00075 | Muromonab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Tgene | C1QA | P02745 | DB00078 | Ibritumomab tiuxetan | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Tgene | C1QA | P02745 | DB00081 | Tositumomab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Tgene | C1QA | P02745 | DB00087 | Alemtuzumab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Tgene | C1QA | P02745 | DB00095 | Efalizumab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Tgene | C1QA | P02745 | DB00108 | Natalizumab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Tgene | C1QA | P02745 | DB00110 | Palivizumab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Tgene | C1QA | P02745 | DB00112 | Bevacizumab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Tgene | C1QA | P02745 | DB00092 | Alefacept | Complement C1q subcomponent subunit A | biotech | approved|investigational|withdrawn |
Top |
RelatedDiseases for TNFRSF14_C1QA |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | TNFRSF14 | C0003873 | Rheumatoid Arthritis | 1 | CTD_human |
| Hgene | TNFRSF14 | C0007570 | Celiac Disease | 1 | CTD_human |
| Tgene | C1QA | C0017661 | IGA Glomerulonephritis | 2 | CTD_human |
| Tgene | C1QA | C0015230 | Exanthema | 1 | CTD_human |
| Tgene | C1QA | C0017662 | Glomerulonephritis, Membranoproliferative | 1 | CTD_human |
| Tgene | C1QA | C0020951 | Immune Complex Diseases | 1 | CTD_human |
| Tgene | C1QA | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Tgene | C1QA | C0024141 | Lupus Erythematosus, Systemic | 1 | CTD_human |
| Tgene | C1QA | C0036341 | Schizophrenia | 1 | PSYGENET |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|